Government health officials need to take immediate action to fully enforce the law against drug makers who are denying 340B drug discounts to providers who use contract pharmacies to dispense 340B-priced drugs, U.S. Senator Joe Manchin (D-W.VA.) and U.S. Senator
…
The U.S. Health Resources Services Administration (HRSA) has ordered South Carolina-based VistaPharm, a manufacturer of generic and over-the-counter (OTC) drugs to repay overcharges to 340B covered entities after a HRSA audit showed the company did not offer its products at the
…
340B stakeholders are responding to a long investigative article in Saturday’s New York Times that accuses a Catholic health system of exploiting the 340B discount program at the expense of one of its inner-city hospitals to enrich its other hospitals
…
The Arkansas Insurance Department (AID) published a rule this week that gives force to the state’s ground-breaking 2021 law prohibiting drug makers from denying 340B pricing or restricting access to drugs when covered entities contract with pharmacies to
…
Drug manufacturer Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.
The U.S. Health Resources and Services Administration (HRSA) is letting eligible healthcare providers in Puerto Rico enroll in the 340B program immediately in light of Hurricane Fiona.
340B stakeholders have offered federal healthcare officials conflicting advice about how best to respond to the U.S. Supreme Court’s June decision striking down a nearly 30% cut in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs.
Generic drug manufacturer Unichem says a 340B compliance audit found it overcharged only two entities and the repayment to both totals just $110.20.
Today is the deadline for public comments on Medicare’s proposed rule for how it will pay for hospital outpatient services and clinician-administered drugs in 2023.
Eighty percent of all hospitals in Medicare’s outpatient prospective payment system—including 52% of all 340B hospitals—would see their net OPPS payments decline next year if Medicare ends a nearly 30% cut in 340B hospitals’ drug payments that began
…*Sign up for news summaries and alerts from 340B Report
